Model N provides cloud-based revenue management solutions specifically designed for the high-tech and life sciences industries. Their platform assists clients in maximizing revenue throughout the commercialization process, which includes improving the quote-to-cash process and enhancing relationships with channel partners. The solutions offered, such as Revenue Cloud for Pharma, Medtech, and High Tech, address the unique pricing, compliance, and revenue management challenges faced by these sectors. Clients subscribe to Model N's software-as-a-service (SaaS) model, allowing them to access a suite of tools and receive ongoing support. This approach not only generates significant savings for customers—averaging $68 million per $1 billion of revenue—but also ensures that they stay updated with industry trends through educational resources. Model N's goal is to empower companies to bring life-changing products to market more efficiently while navigating regulatory changes.

Accel

Accel-KKR

Meritech Capital

SLR Credit Solutions

Vista Equity Partners

Enterprise Software

Healthcare

Model N

AVIZVA, a health-tech organization that offers a variety of solutions for healthcare enterprises, that it has appoints James Vertino as its new CEO.Model N appoints Bret Connor as Chief Executive Officer. The Board of Directors of Blue Shield of California appoints Lois Quam as chief executive officer to lead Blue Shield of California, the first woman to serve as CEO in the health plan’s 86-year history. She joined the company as president in 2024.   Yaqrit, a late-stage biotech and medtech company developing lifesaving treatments for advanced liver diseases appoints Troels Jordansen has joined Yaqrit as Chief Executive Officer.OP Solutions names Michael Kallish as Chief Executive Officer, effective immediately.Access TeleCare appoints Dr. Michael Genovese to Chief Medical Officer for Behavioral Health.Enveda appoints Jason Kim as Chief Financial Officer (CFO).Eko Health appoints of Justin Spencer as Chief Financial Officer (CFO). (Pull from site)Qure.ai appoints Jim Mercadante as its new Chief Commercial Officer. (Pull from site)Symplr, appoints Dr

Recent Digital Health Executive Hires And Promotions: Medidata Expands Team, Carerev, Philips, Eko Health, Others

Model N has appointed Bret Connor as Chief Executive Officer.

Model N Appoints Bret Connor as Chief Executive Officer

Model N Appoints Bret Connor as CEO to Drive Next Phase of Growth. by Healthcare Executive Hires 01/06/2025 Leave a Comment. Bret Connor, CEO at Model NWhat You Should Know: – Model N, a leading provider of revenue optimization and compliance solutions for life sciences and high-tech companies, announced the appointment of Bret Connor as Chief Executive Officer. – Connor brings a wealth of experience in driving customer success and operational excellence, positioning Model N for continued growth and market leadership.  Bret Connor Bio/BackgroundConnor joins Model N from athenahealth, where he served as Chief Operating Officer. During his tenure, he played a key role in the company’s transition to private ownership and spearheaded initiatives focused on client satisfaction and operational excellence. Under his leadership, athenahealth achieved record-high Net Promoter Scores and client retention rates, culminating in a successful recapitalization for $17 billion in 2022. He previously held executive roles at VMware, leading their Professional Services business in the Americas

Model N Appoints Bret Connor As Ceo To Drive Next Phase Of Growth

Latest innovations leverage GenAI and enriched data to strengthen global expansion, compliance, and channel sales.SAN MATEO, Calif. – November 20, 2024 – Model N, the leader in revenue optimization and compliance for life sciences and high-tech companies, launched new generative AI (GenAI) and expanded data capabilities to strengthen its core product suite. Integrating GenAI and intelligent data into the company’s Channel Data Management, Formulary Compliance, and Provider Management solutions showcases Model N's strong commitment to delivering continuous innovation and excellence to the world’s most innovative brands in life sciences and high tech.“The opportunity to harness the power of GenAI and intelligent data to help our customers drive revenue growth, strengthen compliance, and achieve market success couldn’t be greater. As we look ahead, continuing to innovate with AI technologies in our product portfolio remains a top priority – empowering our customers to deliver life-changing products,” said Suresh Kannan, Chief Product Officer, Model N.Bolstering Channel Sales by Leveraging GenAIModel N’s new generative AI Catalog Discovery is a part of its Channel Data Management solution that effectively helps high tech companies manage revenue from indirect sources. GenAI Catalog Discovery automates point-of-sale (POS) data processing, converting unstructured product descriptions into structured, actionable data, regardless of language. High-tech manufacturers can use the AI output to identify how their products are used and bundled for consumption

Model N Introduces Genai And Intelligent Data Innovations To Market-Leading Revenue Optimization And Compliance Offering

Model N Introduces New Rebate Enhancement, as Pharma Companies Prepare for Impact from the Inflation Reduction ActNew Medicare Part D inflation rebate enhancement helps pharma manufacturers manage pricing reformsModel N (NYSE: MODN), the leader in revenue optimization and compliance has introduced a critical product enhancement that supports evolving compliance needs around the Inflation Reduction Act (IRA). The company has introduced a new Medicare Part D inflation rebate-per-unit, ensuring pharma manufacturers remain compliant with impending IRA regulation and avoid significant revenue loss."The Inflation Reduction Act introduces sweeping changes for drug pricing and Medicare programs, and our goal is to empower customers to stay ahead of these shifts," said Suresh Kannan, Chief Product Officer at Model N. "As our life sciences customers prepare for new reforms and regulatory changes, Model N's latest product innovations address a critical market need by providing the capabilities necessary to calculate and process complex Medicare Part D inflation rebates.”According to Model N’s 2024 State of Revenue Report, pharmaceutical executives are preparing for a significant revenue impact from the IRA. The law aims to lower prescription drug costs for Medicare beneficiaries through provisions allowing the program to negotiate prices for certain high-cost drugs and requiring manufacturers to pay rebates for any price changes higher than the inflation rate. Effective for Medicare Part B and D drugs, manufacturers must calculate inflation penalties based on pricing increases over the designated benchmark periods.Model N's new inflation rebate feature empowers customers to calculate Medicare Part D inflation rebate-per-unit, ensuring compliance with the upcoming IRA regulation set to take effect in 2025. Coupled with Model N's Government Pricing, Payer Management, Provider Management, and Validata solutions, customers gain a unified, end-to-end process to manage pricing strategy, calculate fees, and issue rebate payments in compliance with IRA guidance.The company is committed to ensuring that pharma customers are equipped with the most up-to-date technology to comply with IRA guidance, which will continue to evolve into 2026

Model N Introduces New Rebate Enhancement, As Pharma Companies Prepare For Impact From The Inflation Reduction Act

Healthcare & life sciences private equity deal tracker: Vista to acquire Model N for $1.25 billion.

Healthcare & Life Sciences Private Equity Deal Tracker: Vista to Acquire Model N for $1.25 Billion

Pictured: Vintage computer and wasted money/Taylor Tieden for BioSpaceMany pharmaceutical companies are losing revenue due to poor customer data management, according to a recent survey from Model N, which helps clients optimize revenue. Specifically, as much as 6% of pharma revenue leaks out in the form of penalties, incorrect pricing and overpaid rebates. And nearly half of the 304 executives who participated in this year’s survey indicated that their membership data management process is inefficient.The inability to vet formularies—lists of drugs covered by health insurance—was cited as a challenge by 94% of survey respondents, and poor membership data management was a problem for 95% of respondents. These two factors are key issues impacting revenue management in the pharmaceutical industry, according to the report. Respondents listed data accuracy as the topmost issue preventing proper management of customer and membership data. Inaccurate customer data can lead to poor pricing decisions, incorrect rebate payments, revenue loss and even government penalties, according to the report.The Roots of the ProblemJesse Mendelsohn, senior vice president at Model N, told BioSpace that it is common for customers to register details such as names, addresses and identifiers (unique customer markers) that do not correspond across all company records, making it difficult to determine which programs they qualify for

Poor Customer Data Management Costs Pharma Companies Money: Report

Model N (NYSE: MODN), a leader in revenue optimization and compliance for pharmaceutical, medtech, and high-tech innovators, today announced that it h

Model N to be Acquired by Vista Equity Partners For $1.25 Billion

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N (NYSE: MODN), a leader in revenue optimization and compliance for pharmaceutical, medtech, and high-tech innovators, today announced that it has entered into a definitive agreement to be acquired by Vista Equity Partners (“Vista”), a leading global investment firm focused exclusively on enterprise software, data, and technology-enabled businesses. Under the terms of the agreement, Vista will acquire all the outstanding shares of Model N common stock for $30.00 per share in an all-cash transaction valued at approximately $1.25 billion. The purchase price represents a premium of approximately 23% over Model N’s 30-trading-day volume weighted average share price as of the close on January 10, 2024, the day prior to the Model N Board of Directors authorizing its financial advisor to contact potential acquirors, and a premium of approximately 16% over Model N’s 30-trading-day volume weighted average share price as of the close on April 5, 2024. “We are pleased to have reached this agreement with Vista, which is the culmination of a robust sale process led by our Board of Directors with the assistance of our financial and legal advisors,” said Baljit Dail, Chairman of the Model N Board. “As the Board considered the long-term path for Model N, we unanimously determined that the transaction with Vista represents the best opportunity to deliver compelling, certain, and immediate cash value to our stockholders and is in their best interest in light of the challenges faced by Model N as a standalone public company.”

Model N To Be Acquired By Vista Equity Partners For $1.25 Billion

Crystal Financial, an independent commercial finance company, provided a $50 million term loan facility for Model N to support its acquisition of Revitas.

Crystal Financial Supports Model N’s Revitas Buy - ABFJournal

Cloud-based revenue management solutions provider

Model N

Cloud-based revenue management solutions provider

Model N

Cloud-based revenue management solutions provider

About

Simplify's Take

What believers are saying

What critics are saying

What makes Model N unique

6 month growth

1 year growth

2 year growth

Benefits

Recently Posted Jobs

Model N is Hiring for 0 Jobs on Simplify!